Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms.

Johansson P, Mesa R, Scherber R, Abelsson J, Samuelsson J, Birgegård G, Andréasson B.

Leuk Lymphoma. 2012 Mar;53(3):441-4. doi: 10.3109/10428194.2011.619608. Epub 2011 Oct 24.

PMID:
21883029
2.

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA.

Blood. 2011 Jul 14;118(2):401-8. doi: 10.1182/blood-2011-01-328955. Epub 2011 May 2.

3.

Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms.

Abelsson J, Andréasson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, Emanuel R, Mesa R, Johansson P.

Leuk Lymphoma. 2013 Oct;54(10):2226-30. doi: 10.3109/10428194.2013.766732. Epub 2013 Jul 29.

PMID:
23398206
4.

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.

Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA.

Cancer. 2016 Jun 15;122(12):1888-96. doi: 10.1002/cncr.30013. Epub 2016 Apr 12.

5.

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA.

J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590. Ferarri, Maria L [corrected to Ferrari, Maria L].

6.

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A.

Cancer. 2007 Jan 1;109(1):68-76.

7.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

8.

Quality of life in MPN comes of age as a therapeutic target.

Scherber RM, Geyer HL, Mesa RA.

Curr Hematol Malig Rep. 2014 Dec;9(4):324-30. doi: 10.1007/s11899-014-0239-9. Review.

PMID:
25262210
9.

Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.

Anderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, de Vocht F, Clarke M, McMullin MF.

Am J Hematol. 2015 Oct;90(10):864-70. doi: 10.1002/ajh.24098. Epub 2015 Sep 10.

10.

[Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].

Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.

Zhonghua Zhong Liu Za Zhi. 2009 Jul;31(7):510-4. Chinese.

PMID:
19950698
11.

Assessment of pain, fatigue, sleep and quality of life (QoL) in elderly hospitalized cancer patients.

Eyigor S, Eyigor C, Uslu R.

Arch Gerontol Geriatr. 2010 Nov-Dec;51(3):e57-61. doi: 10.1016/j.archger.2009.11.018. Epub 2009 Dec 30.

PMID:
20044154
12.

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.

Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, Geyer HL, McCallister A, Cotter M, Van Husen B, Harrison CN, Mesa RA.

Cancer. 2016 Feb 1;122(3):477-85. doi: 10.1002/cncr.29753. Epub 2015 Dec 15.

13.

Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy.

Lilleby W, Fosså SD, Waehre HR, Olsen DR.

Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):735-43.

PMID:
10098428
14.

Validation of the German version of the brief fatigue inventory.

Radbruch L, Sabatowski R, Elsner F, Everts J, Mendoza T, Cleeland C.

J Pain Symptom Manage. 2003 May;25(5):449-58.

PMID:
12727043
15.

High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms.

Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J, Girodon F, Andréasson B.

Eur J Intern Med. 2015 Jun;26(5):344-7. doi: 10.1016/j.ejim.2015.03.009. Epub 2015 Apr 8.

PMID:
25863408
16.

Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis.

Pettersson H, Knutsen H, Holmberg E, Andréasson B.

Eur J Haematol. 2015 Feb;94(2):152-6. doi: 10.1111/ejh.12410. Epub 2014 Jul 24.

PMID:
25039361
17.

A cross-sectional study of fatigue and sleep quality before and after kidney transplantation.

Rodrigue JR, Mandelbrot DA, Hanto DW, Johnson SR, Karp SJ, Pavlakis M.

Clin Transplant. 2011 Jan-Feb;25(1):E13-21. doi: 10.1111/j.1399-0012.2010.01326.x. Epub 2010 Oct 21.

PMID:
20961334
18.

Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice.

Butt Z, Wagner LI, Beaumont JL, Paice JA, Peterman AH, Shevrin D, Von Roenn JH, Carro G, Straus JL, Muir JC, Cella D.

J Pain Symptom Manage. 2008 Jan;35(1):20-30. Epub 2007 Oct 23.

PMID:
17959345
20.

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.

Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, Park MR, Chi HS, Kim HY, Kim HJ, Lee MH, Kim H, Won JH, Yoon HJ, Oh DY, Nam EM, Bae SH, Kim BK; Korean MPN Working Party.

Thromb Haemost. 2009 Mar;101(3):547-51.

PMID:
19277418

Supplemental Content

Support Center